AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein-tyrosine kinase 2-beta

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q14289

UPID:

FAK2_HUMAN

Alternative names:

Calcium-dependent tyrosine kinase; Calcium-regulated non-receptor proline-rich tyrosine kinase; Cell adhesion kinase beta; Focal adhesion kinase 2; Proline-rich tyrosine kinase 2; Related adhesion focal tyrosine kinase

Alternative UPACC:

Q14289; D3DST0; Q13475; Q14290; Q16709; Q6PID4

Background:

Protein-tyrosine kinase 2-beta, also known as Calcium-dependent tyrosine kinase, plays a pivotal role in various cellular processes including actin cytoskeleton reorganization, cell migration, and immune response regulation. It is essential for normal B-cell migration in the spleen, macrophage polarization, and T-cell responses. Additionally, it contributes to bone remodeling by promoting osteoclastic bone resorption and may inhibit osteoprogenitor cell differentiation.

Therapeutic significance:

Understanding the role of Protein-tyrosine kinase 2-beta could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.